Heart valve repair

Children's Hospital of Philadelphia Receives Multi-Million Dollar Gift from Topolewski Family to Advance Pediatric Heart Valve Research and Establish Endowed Chair in Cardiology

Retrieved on: 
Thursday, May 18, 2023
Surgeon, Ventricular septal defect, The Center, CHOP, Heart valve repair, Medulla oblongata, FACC, Cardiovascular disease, Research, Cora, Cardiology, Frontier, VSD, Patient, Division, Map, Mortimer, Knowledge, Infant, Hospital, Topolewski v. State, Children's Hospital of Philadelphia, Pharmaceutical industry, Dentistry, Medical device, Nursing, Annals of Pediatric Cardiology, FAAP, MD

PHILADELPHIA, May 18, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) announced that it has received a multi-million dollar gift from the Topolewski family, longstanding supporters of the Cardiac Center at CHOP , to establish the Topolewski Pediatric Heart Valve Center .

Key Points: 
  • PHILADELPHIA, May 18, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) announced that it has received a multi-million dollar gift from the Topolewski family, longstanding supporters of the Cardiac Center at CHOP , to establish the Topolewski Pediatric Heart Valve Center .
  • The Topolewski Pediatric Heart Valve Center brings together a comprehensive team of cardiac surgeons, cardiologists, scientists, researchers, and experts in interventional cardiology and cardiac imaging to revolutionize pediatric cardiac care.
  • This multidisciplinary group takes a coordinated approach and is working to develop precise, evidence-based long-term solutions for infants and children with heart valve disease.
  • As part of the Topolewski family gift, Dr. Jolley will hold the inaugural Topolewski Endowed Chair in Pediatric Cardiology.

Vivasure Medical Announces Development of Sutureless Venous Closure Device for Use in Percutaneous Transcatheter Procedures

Retrieved on: 
Thursday, July 15, 2021
Biotechnology, General Health, Surgery, Health, Cardiology, Cardiac surgery, Medical specialties, Anatomy, Clinical medicine, Mitral valve replacement, Heart valve repair, Mitral valve, Heart valve, Edwards Lifesciences, Lutembacher's syndrome

PerQseal Blue is designed exclusively for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, such transcatheter mitral valve repair or replacement (TMVR) and transcatheter tricuspid valve repair or replacement (TTVR).

Key Points: 
  • PerQseal Blue is designed exclusively for sutureless and fully absorbable large-bore venous vessel closure following percutaneous cardiovascular procedures, such transcatheter mitral valve repair or replacement (TMVR) and transcatheter tricuspid valve repair or replacement (TTVR).
  • As transcatheter procedures for mitral and tricuspid valve treatment become increasingly common, there is a growing need for new venous closure options.
  • PerQseal Blue has the potential to be the first sutureless, fully absorbable synthetic implant for large-bore venous closure following these catheter-based procedures.
  • Were thrilled to introduce PerQseal Blue to our product development portfolio as a potential new option specifically for large-bore venous closure following percutaneous cardiovascular procedures, said Andrew Glass, CEO of Vivasure Medical.

Global Tricuspid Valve Repair Market (2021 to 2025) - Size & Forecast with Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 11, 2021
Surgery, Health, Cardiology, Medical specialties, Anatomy, Valvular heart disease, Circulatory system, Cardiac surgery, Tricuspid valve stenosis, Heart valve repair, Tricuspid insufficiency, Tricuspid valve, Heart valve, Regurgitation, Stenosis

Tricuspid valve disease often transpires with other heart valve problems.

Key Points: 
  • Tricuspid valve disease often transpires with other heart valve problems.
  • There are primarily two types of tricuspid valve disease that are tricuspid regurgitation (TR) and tricuspid stenosis.
  • For the treatment of patient's with such kind of disease tricuspid valve repair and tricuspid valve replacement treatments are opted such treatment cure diseases affecting the tricuspid valve.
  • Though, the growth of global tricuspid valve repair market would be negatively impacted by various challenges.

Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair

Retrieved on: 
Thursday, April 8, 2021
Anatomy, Medical specialties, Heart, Cardiac surgery, Valvular heart disease, Heart valves, Cardiology, Heart valve repair, Tricuspid valve, Heart valve, Tricuspid insufficiency, Regurgitation

ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR).

Key Points: 
  • ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR).
  • The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient's unique anatomy.
  • When those leaflets do not close properly, blood can flow in the reverse direction known as regurgitation forcing the heart to work harder.
  • "This newest generation device further improves cardiologists' ability to safely and effectively repair the tricuspid valve, which historically has been extremely challenging to treat."

Cardio Industry Executive Ed Rieflin Appointed to Chair Vvital Biomed

Retrieved on: 
Wednesday, April 7, 2021
Medical specialties, Cardiac surgery, Anatomy, Heart, Valvular heart disease, Cardiology, Regurgitation, Mitral valve, Heart valve repair, Mitral insufficiency, Heart valve

MISGAV, Israel, April 7, 2021 /PRNewswire/ -- Vvital Biomed Ltd. ("Vvital"), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced the appointment of Ed Rieflin as Chair of the Board.

Key Points: 
  • MISGAV, Israel, April 7, 2021 /PRNewswire/ -- Vvital Biomed Ltd. ("Vvital"), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced the appointment of Ed Rieflin as Chair of the Board.
  • Commenting on the appointment Rieflin said, "Long-term treatment solutions to mitral valve regurgitation are the holy grail of this sector.
  • Vvital CMO, Aram Smolinsky MD, the heart surgeon who introduced mitral valve repair to Israel and inventor of the Vvital solution, further elucidates, "Vvital's procedure immediately repairs the mitral valve regurgitation.
  • Vvital CEO, Nir Golan remarked, "A true industry expert, Ed Rieflin is a great addition to our company.

The Foundry Announces Successful First-In-Human Procedure In Study Of Innovative Transcatheter Mitral Valve Repair Technology

Retrieved on: 
Monday, January 11, 2021
Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Valvular heart disease, Mitral valve, Cardiology, Heart valve repair, Heart valve, Mitral insufficiency, Regurgitation, Mitral valve replacement

The investigational Half Moon mitral valve repair device, developed through a unique partnership between Medtronic (NYSE:MDT) and The Foundry, is designed to restore function in a diseased mitral valve in patients with severe symptomatic mitral regurgitation (MR), a disease where blood leaks backwards within the heart due to the mitral valve's inability to close properly.

Key Points: 
  • The investigational Half Moon mitral valve repair device, developed through a unique partnership between Medtronic (NYSE:MDT) and The Foundry, is designed to restore function in a diseased mitral valve in patients with severe symptomatic mitral regurgitation (MR), a disease where blood leaks backwards within the heart due to the mitral valve's inability to close properly.
  • "Minimally invasive transcatheter heart valve repair can offer relief from mitral valve regurgitation without the need for traditional open-heart surgery," said Howard Song, M.D., Ph.D., OHSU cardiothoracic surgery division chief, who co-led the procedure.
  • The Half Moon mitral valve repair device is unique from other mitral valve repair technologies in maintaining more natural physiologic functionality of the mitral valve.
  • It is deployed using a transfemoral (through the leg) delivery catheter, which is navigated through the vasculature to the diseased native mitral valve.

Edwards Treats First Patient In U.S. Clinical Trial Evaluating Minimally Invasive Device For Mitral Valve Disease

Retrieved on: 
Monday, December 21, 2020
Cardiac surgery, Medical specialties, Valvular heart disease, Clinical medicine, Medicine, Mitral valve, Mitral insufficiency, Regurgitation, Heart valve repair, Mitral valve replacement, Heart valve, MitraClip

The HARPOON system uses a less-invasive technique than open-heart surgery in order to treat a type of heart disease called severe degenerative mitral valve regurgitation, which occurs when there is damage to the mitral valve that prevents proper functioning of the valve.

Key Points: 
  • The HARPOON system uses a less-invasive technique than open-heart surgery in order to treat a type of heart disease called severe degenerative mitral valve regurgitation, which occurs when there is damage to the mitral valve that prevents proper functioning of the valve.
  • The HARPOON system, which was developed by researchers at the University of Maryland Heart and Vascular Center, requires only a small incision to repair the mitral valve.
  • The RESTORE clinical trial is an investigational device exempt study that will enroll and follow up to 360 patients who need mitral valve repair surgery due to severe degenerative mitral valve regurgitation.
  • Degenerative mitral valve regurgitation is commonly caused by mitral valve prolapse, which prevents the valve from closing properly and causes blood to leak backwards as the heart contracts.

Abbott Receives CE Mark for Next-Generation MitraClip™ Heart Valve Repair Device to Treat Mitral Regurgitation

Retrieved on: 
Monday, September 21, 2020
Medical specialties, Cardiac surgery, Medicine, Circulatory system, Interventional cardiology, MitraClip, Cardiology, Mitral valve repair, Mitral valve, Heart valve repair, Valvular heart disease, Heart valve

ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world.

Key Points: 
  • ABBOTT PARK, Ill., Sept. 21, 2020 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its fourth-generation MitraClip Transcatheter Mitral Valve Repair System, the leading minimally invasive mitral valve repair device in the world.
  • Known as MitraClip G4, the device is now approved for use in Europe and other countries that recognize CE Mark as a non-surgical option for the treatment of mitral regurgitation (MR), or a leaky heart valve.
  • While medication can help people manage the symptoms of MR, it does not treat the leaky valve itself.
  • Once in place, MitraClip restores the proper functioning of the mitral valve and the heart's ability to pump oxygenated blood more efficiently.

Annuloplasty Rings Market Analysis Highlights the Impact of COVID-19 (2020-2024) | Increasing Prevalence of Heart Valve Diseases to Boost the Market Growth | Technavio

Retrieved on: 
Wednesday, August 12, 2020
Medical devices, Health, Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Mitral valve replacement, Valvular heart disease, Mitral valve, Heart valve repair, Valve replacement, Heart valve

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities.
  • Download a Free Sample Report on COVID-19 Impacts
    Based on segmentation by application, which is the leading segment in the market?
  • Increasing prevalence of heart valve diseases and increasing preference of mitral valve repair over mitral valve replacement are the major factors driving the market.

MOGAS Industries, Inc. Acquires Watson Valve Assets

Retrieved on: 
Wednesday, July 1, 2020
Engineering, Chemicals, Plastics, Other Energy, Utilities, Manufacturing, Oil, Gas, Coal, Nuclear, Alternative energy, Energy, Other Natural Resources, Mining, Minerals, Natural Resources, Other Manufacturing, Plumbing, Autoclave, Mogas, Valve, Heart valve repair, Heart valve, Video game companies, Construction, Video gaming, MOGAS Group

MOGAS Industries, Inc. recently completed the acquisition of assets of Watson Valve , a Houston-based turn-key manufacturer of severe service valves, to include repairs and coating services.

Key Points: 
  • MOGAS Industries, Inc. recently completed the acquisition of assets of Watson Valve , a Houston-based turn-key manufacturer of severe service valves, to include repairs and coating services.
  • Watson has a global install base of over 3,400 valves, primarily in the mining industry, but also encompassing the oil & gas and chemical industries.
  • This strategic purchase expands MOGAS global mining reach on valve supply and valve repair services , as well as adjacent market opportunities especially pertaining to the autoclave market.
  • Matt Mogas, MOGAS President and CEO, said: This acquisition allows MOGAS to expand its product portfolio and get a step closer to achieve our vision as the dominant severe service technology company.